Back to All Articles
You must be logged in to create a new articleBrowse articles with tag: Hatch-waxman
All Articles
District Court Finds the FDA Reasonably De-listed Eli Lilly’s Weight Loss Drug From Drug Shortage List
Written by: Rhett D. Ramsey and Robert J. Hilton, Ph.D. Congress authorized the FDA to determine whether a drug is “in... Read More
Introducing the 2024 ANDA Litigation Intelligence Report: Insights into the Competitive Pharmaceutical Landscape
As the pharmaceutical industry continues to face an ever-changing legal environment, staying informed about trends in ANDA litigation has never... Read More
Patexia Insights 215: Benefits and Challenges of Multidistrict Litigations in Hatch-Waxman cases
When several ANDA filers seek approval for the same drug, a branded pharmaceutical company may struggle to bring Hatch-Waxman Act... Read More
Patexia Insight 196: Top ANDA Firms of 2023
In late August of this year, our ANDA Intelligence 2023 Report was released, a comprehensive study, covering the Hatch-Waxman litigation... Read More
Exploring the Use of 'March-In' Rights: Biden Administration's Consideration on Drug Patents and Pricing
The Biden administration is exploring the use of "march-in" rights established in the 1980 Bayh-Dole Act, which has never... Read More
Patexia Insight 185: From Flux to Surge: Is ANDA Litigation Rising?
We are proud to announce that tomorrow marks the release of the fourth edition of our ANDA Litigation Intelligence Report.... Read More